UCSF Founded NewCo, Erasca, Announces First Patient Dosed in HERKULES-2
September 13, 2021
UCSF technology founded NewCo, Erasca, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced dosing of the first patient in the Catalyst Awardees Win the Harrington Innovator-Scholar Award
September 01, 2021
Jennifer Chen and John Chorba, two UCSF Catalyst awardees, win the 2021 Harrington Innovator-Scholar Award for projects that also won the Catalyst Award.
MORE
FDA Accepts Epygenix Therapeutics IND to Initiate a Clinical Trial
September 01, 2021
Epygenix Therapeutics, Inc. ("Epygenix"), a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced today that the U.S. eFFECTOR Debuts as Publicly Traded Next-Generation Oncology Company
August 27, 2021
eFFECTOR Therapeutics, a clinical-stage biotech company co-founded by University of California Professor of
Urology Davide Ruggero and Cellular and Molecular Pharmacologist Kevan Shokat, today completed its business combination with Locust Walk Acquisition Corp. eFFECTOR Therapeutics expects its... Encellin Closes $5.9M Seed Financing
August 12, 2021
Encellin, a personalized regenerative medicine biotech company, founded at the University of California San Francisco (UCSF), and developing novel cell-based approaches to deliver sustained therapies with a single implant, today announced the closing of a $5.9M Seed financing round. The round was... UCSF Health Awards Returns for 3rd Year and Includes Life Sciences Awards
By Melissa Faukner on August 09, 2021
Preview Video Link for the Award Show can be viewed here Sonoma Biotherapeutics Raises $265M
August 05, 2021
Biotech company Sonoma Biotherapeutics has raised $265 million in new funding, the company announced Wednesday. The funding will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and type 1 diabetes. Epygenix Therapeutics to Proceed With Trial for the Treatment of Dravet Syndrome
August 03, 2021
Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy that uses UCSF technology developed by Dr. Scott Baraban, is pleased to announce that the company's ARGUS trial with EPX-100 (Clemizole Hydrochloride) in patients with Dravet syndrome... RxSight sets terms for $125 million IPO
July 27, 2021
RxSight, a commercial med-tech company based on UCSF post-cataract intraocular lens technology, announced terms for its IPO on Monday. The company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18.
MORE
Erasca Announces Closing of Initial Public Offering
July 21, 2021
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of its initial public offering of 21,562,500 shares of common stock, which includes...